Apricot Seeds (Laetrile/B17): Debunked Cancer Treatment

What Are Apricot Seeds and Laetrile?

Apricot seeds are the kernels found inside apricot pits, containing high concentrations of amygdalin, a cyanogenic glycoside. In the 1970s, biochemist Ernst Krebs Jr. extracted and purified amygdalin, marketing it as "laetrile" or "vitamin B17" (though it's not actually a vitamin). Proponents claimed this compound could selectively target cancer cells while leaving healthy tissue unharmed.

The theory behind laetrile centers on the idea that cancer cells contain higher levels of beta-glucosidase enzyme, which would theoretically break down amygdalin to release cyanide specifically in tumors. However, this mechanism has never been validated in human studies, and the premise itself is flawed.

Proposed Mechanism of Action

Laetrile advocates propose a selective toxicity mechanism where amygdalin breaks down into benzaldehyde, glucose, and hydrogen cyanide when exposed to beta-glucosidase enzyme. The theory suggests cancer cells have more of this enzyme and less rhodanese (which detoxifies cyanide), making them more susceptible to cyanide poisoning than normal cells.

Recent preclinical studies have explored other potential mechanisms. Pak et al. (2021, PMID: 32510292) found that apricot seed extract induced mitochondrial-mediated apoptosis in liver cancer cell lines, while Mohammadi et al. (2020, PMID: 32026321) reported increased Bax/Bcl-2 ratio and caspase-3 expression in pancreatic cancer cells.

However, these laboratory findings don't translate to clinical benefit. The concentrations used in cell culture studies are often far higher than what's achievable safely in humans, and the controlled laboratory environment doesn't reflect the complexity of human physiology.

Human Evidence: Consistently Negative

The human evidence for laetrile is overwhelmingly negative. The most comprehensive evaluation came from a National Cancer Institute (NCI) sponsored clinical trial published in the New England Journal of Medicine in 1982. This study followed 178 patients with advanced cancer who received laetrile according to the exact protocol used by laetrile proponents.

The results were unambiguous: no patient experienced tumor regression, and the median survival was no different from what would be expected without treatment. Several patients developed symptoms of cyanide poisoning, including nausea, vomiting, headache, and dizziness.

A systematic review by the Cochrane Collaboration examined all available evidence on laetrile and concluded there was no reliable evidence to support its use as a cancer treatment. The review noted that "the claims that laetrile has beneficial effects for cancer patients are not currently supported by sound clinical data."

Unlike evidence-based treatments reviewed on this site such as fenbendazole or high-dose vitamin C, which show promising signals in human studies, laetrile has consistently failed to demonstrate any anti-cancer activity across multiple well-designed trials.

Safety Concerns and Toxicity

The safety profile of apricot seeds and laetrile is particularly concerning. A 2021 study by Hussain et al. (PMID: 34799332) evaluated the hepatic and renal toxicity of apricot seeds in rats, finding dose-dependent organ damage with chronic administration.

The primary safety concern is cyanide poisoning. When amygdalin is broken down by intestinal bacteria or tissue enzymes, it releases hydrogen cyanide, a potent cellular toxin that blocks cellular respiration. Symptoms of cyanide poisoning include:

• Nausea and vomiting
• Headache and dizziness
• Difficulty breathing
• Rapid heart rate
• Mental confusion
• Coma and death in severe cases

The European Food Safety Authority has established that consuming more than 3 small apricot kernels (or less than half of a large kernel) can exceed safe cyanide levels for adults. Children are at even greater risk due to their lower body weight.

A 2020 study by Michalak et al. (PMID: 31724244) found that long-term administration of bitter apricot seeds negatively affected cortical bone microstructure in rabbits, suggesting additional systemic toxicity beyond acute cyanide poisoning.

Recent Research Findings

While recent studies continue to explore amygdalin's effects in laboratory settings, they consistently fail to provide evidence supporting clinical use. Saleh et al. (2021, PMID: 34577581) reviewed amygdalin's multiple cellular actions, noting effects on female reproduction that raise additional safety concerns.

Genotoxicity studies present mixed results. Aydin et al. (2020, PMID: 32794256) found both genotoxic and antigenotoxic effects of amygdalin on human lymphocytes using the comet assay, depending on concentration and exposure conditions. This inconsistency further undermines any therapeutic rationale.

A 2021 ethnopharmacological study (PMID: 34146630) examined apricot kernel extracts in various cell lines but acknowledged that "further studies are needed to evaluate the safety and efficacy in clinical settings." This cautious conclusion is typical of responsible researchers who recognize the gap between laboratory findings and clinical application.

Regulatory Status and Medical Position

The FDA banned laetrile for cancer treatment in 1980 following extensive review of safety and efficacy data. The agency continues to warn against laetrile use and has taken enforcement action against companies making cancer treatment claims.

Major cancer organizations worldwide maintain consistent positions against laetrile:

• American Cancer Society: "Available scientific evidence does not support claims that laetrile is effective in treating cancer"
• National Cancer Institute: "No controlled clinical trials of laetrile have been completed"
• Cancer Research UK: "There is no scientific evidence that laetrile can treat cancer"

This unanimous rejection by medical authorities contrasts sharply with the ongoing research interest in compounds like mebendazole or dichloroacetate, which continue to advance through clinical development.

Why the Persistent Appeal?

Despite overwhelming negative evidence, laetrile maintains a following in alternative cancer communities. Several factors contribute to this persistence:

Natural Appeal: The "natural" origin of apricot seeds appeals to those seeking alternatives to conventional chemotherapy, even though natural doesn't equal safe or effective.

Conspiracy Theories: Some proponents claim pharmaceutical companies suppress laetrile because it can't be patented. This ignores the fact that many effective cancer drugs are derived from natural sources and that generic medications are widely used.

Anecdotal Reports: Testimonials and case reports, while emotionally compelling, don't constitute scientific evidence. Spontaneous remissions, placebo effects, and concurrent treatments can create false impressions of efficacy.

Desperation: Patients facing terminal diagnoses may be willing to try anything, making them vulnerable to unproven treatments regardless of risk.

Evidence-Based Alternatives

Rather than pursuing debunked treatments like laetrile, patients interested in complementary approaches should consider evidence-based options with better safety profiles and research support:

Repurposed Drugs: Compounds like ivermectin and mebendazole for lung cancer show genuine promise in early clinical studies while maintaining established safety profiles.

Metabolic Approaches: The press-pulse protocol combines dietary interventions with targeted treatments based on sound metabolic principles.

Prevention Strategies: For those focused on prevention, compounds like melatonin have substantial research support and excellent safety profiles.

These approaches differ fundamentally from laetrile in that they're based on evolving positive evidence rather than disproven theories.

Integration with Conventional Care

Any complementary cancer approach should be integrated with, not substituted for, evidence-based conventional treatment. The Cancer Prevention Lab protocol emphasizes this integration, combining the best of conventional and complementary medicine based on scientific evidence.

Patients considering any alternative treatment should discuss options with their oncology team. Unlike laetrile, many repurposed drugs and natural compounds can be safely combined with standard treatments when properly monitored.

The Importance of Evidence Standards

The laetrile story illustrates why rigorous evidence standards matter in cancer treatment. Laboratory studies showing anti-cancer effects are just the first step in a long development process. Without positive human trials, these findings remain scientifically interesting but clinically irrelevant.

This site maintains strict evidence grading precisely to help patients distinguish between promising early-stage research and thoroughly debunked treatments. While we're open to unconventional approaches when supported by data, we're equally committed to identifying treatments that have failed scientific scrutiny.

Conclusion

Apricot seeds and laetrile represent a cautionary tale in cancer treatment. Despite decades of research, multiple clinical trials, and ongoing laboratory studies, no credible evidence supports their anti-cancer efficacy. The documented toxicity risks, including potentially fatal cyanide poisoning, far outweigh any theoretical benefits.

Patients seeking complementary cancer treatments have better options with stronger evidence bases and superior safety profiles. The key is distinguishing between treatments that have failed scientific testing and those that show genuine promise in early research.

For those committed to exploring all options, focus on approaches with positive human data and established safety profiles rather than treatments that have been thoroughly debunked by decades of negative research.